FdaApplication
NDA 021187
Identifiers
- fda_app_no: NDA021187
Properties
| Property | Value |
|---|---|
| applicant_name | ORGANON USA LLC A SUB OF ORGANON AND CO |
| application_type | NDA |
| approval_date | 2001-10-03 |
Revenue by product
NUVARING
| Period | Revenue |
|---|---|
| Q2 2026 | $27.0M* |
| Q1 2026 | $24.0M* |
| Q4 2025 | $16.0M* |
| Q3 2025 | $26.0M* |
| Q2 2025 | $28.0M* |
| Q1 2025 | $22.0M* |
| Q4 2024 | $25.0M* |
| Q3 2024 | $23.0M* |
| Q2 2024 | $29.0M* |
| Q1 2024 | $38.0M* |
| Q4 2023 | $35.0M* |
| Q3 2023 | $37.0M* |
| Q2 2023 | $46.0M* |
| Q1 2023 | $49.0M* |
| Q4 2022 | $40.0M* |
| Q3 2022 | $50.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NUVARING | ETHINYL ESTRADIOL; ETONOGESTREL | 0.015MG/24HR;0.12MG/24HR | RING;VAGINAL |
1 product